Cargando…
Hypothesis: What is the Best We Can Do with Hydroxychloroquine for COVID-19?
There are widespread anecdotal reports of seemingly successful treatment among the early (three to seven days from symptoms) stage coronavirus disease 2019 (COVID-19) patients with the drug hydroxychloroquine (HCQ), and randomized placebo-controlled trials of HCQ in outpatient settings are underway....
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585824/ https://www.ncbi.nlm.nih.gov/pubmed/33116907 http://dx.doi.org/10.2147/CLEP.S277889 |
_version_ | 1783599871188533248 |
---|---|
author | Wang, Shuncong Mulier, Stefaan Jonscher, Charles Ye, Sheng Chen, Lei Feng, Yuanbo Li, Yue Ni, Yicheng |
author_facet | Wang, Shuncong Mulier, Stefaan Jonscher, Charles Ye, Sheng Chen, Lei Feng, Yuanbo Li, Yue Ni, Yicheng |
author_sort | Wang, Shuncong |
collection | PubMed |
description | There are widespread anecdotal reports of seemingly successful treatment among the early (three to seven days from symptoms) stage coronavirus disease 2019 (COVID-19) patients with the drug hydroxychloroquine (HCQ), and randomized placebo-controlled trials of HCQ in outpatient settings are underway. In this note, we (1) report observational evidence and present scientific reasoning as to why early treatment with HCQ may succeed while treatment later in the disease progression is likely to fail and (2) hypothesize a public health regime under which HCQ may be used to mitigate the impact of the current pandemic. |
format | Online Article Text |
id | pubmed-7585824 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-75858242020-10-27 Hypothesis: What is the Best We Can Do with Hydroxychloroquine for COVID-19? Wang, Shuncong Mulier, Stefaan Jonscher, Charles Ye, Sheng Chen, Lei Feng, Yuanbo Li, Yue Ni, Yicheng Clin Epidemiol Hypothesis There are widespread anecdotal reports of seemingly successful treatment among the early (three to seven days from symptoms) stage coronavirus disease 2019 (COVID-19) patients with the drug hydroxychloroquine (HCQ), and randomized placebo-controlled trials of HCQ in outpatient settings are underway. In this note, we (1) report observational evidence and present scientific reasoning as to why early treatment with HCQ may succeed while treatment later in the disease progression is likely to fail and (2) hypothesize a public health regime under which HCQ may be used to mitigate the impact of the current pandemic. Dove 2020-10-20 /pmc/articles/PMC7585824/ /pubmed/33116907 http://dx.doi.org/10.2147/CLEP.S277889 Text en © 2020 Wang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Hypothesis Wang, Shuncong Mulier, Stefaan Jonscher, Charles Ye, Sheng Chen, Lei Feng, Yuanbo Li, Yue Ni, Yicheng Hypothesis: What is the Best We Can Do with Hydroxychloroquine for COVID-19? |
title | Hypothesis: What is the Best We Can Do with Hydroxychloroquine for COVID-19? |
title_full | Hypothesis: What is the Best We Can Do with Hydroxychloroquine for COVID-19? |
title_fullStr | Hypothesis: What is the Best We Can Do with Hydroxychloroquine for COVID-19? |
title_full_unstemmed | Hypothesis: What is the Best We Can Do with Hydroxychloroquine for COVID-19? |
title_short | Hypothesis: What is the Best We Can Do with Hydroxychloroquine for COVID-19? |
title_sort | hypothesis: what is the best we can do with hydroxychloroquine for covid-19? |
topic | Hypothesis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585824/ https://www.ncbi.nlm.nih.gov/pubmed/33116907 http://dx.doi.org/10.2147/CLEP.S277889 |
work_keys_str_mv | AT wangshuncong hypothesiswhatisthebestwecandowithhydroxychloroquineforcovid19 AT mulierstefaan hypothesiswhatisthebestwecandowithhydroxychloroquineforcovid19 AT jonschercharles hypothesiswhatisthebestwecandowithhydroxychloroquineforcovid19 AT yesheng hypothesiswhatisthebestwecandowithhydroxychloroquineforcovid19 AT chenlei hypothesiswhatisthebestwecandowithhydroxychloroquineforcovid19 AT fengyuanbo hypothesiswhatisthebestwecandowithhydroxychloroquineforcovid19 AT liyue hypothesiswhatisthebestwecandowithhydroxychloroquineforcovid19 AT niyicheng hypothesiswhatisthebestwecandowithhydroxychloroquineforcovid19 |